Sleep Disorders Treatment Drugs Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 – 2034

Sleep Disorders Treatment Drugs Market Size

The global sleep disorders treatment drugs market had a significant revenue in 2024 and is expected to grow at a CAGR from 2025-2034, due to the increasing awareness regarding sleep health, increasing diagnoses of sleep disorders, and increasing availability of medication solutions. According to Sleep Foundation.org, Obstructive sleep apnea (OSA) affects over one billion adults around the globe, with studies showing it is estimated that 80-90% of patients are undiagnosed.
 

Sleep disorders - such as insomnia, obstructive sleep apnea, narcolepsy, and restless leg syndrome - impact millions of people irrespective of their demographic or lifestyle factors, impacting the quality of life while also creating increased risk for comorbidities including depression, obesity, and cardiovascular disease. The increased elderly populations at greater risk for being impacted by disrupted sleep cycles are also a driving force in this market expansion.
 

On top of this, increased stress, poor sleep hygiene, and unlimited access to electronic devices have driven the increased level of sleep disorders that younger populations experience daily. Consequently, the demand for targeted pharmaceutical treatments has boomed, including benzodiazepines, non-benzodiazepine hypnotics, melatonin receptor agonists, and orexin receptor antagonists that result in specific treatment. In addition, recent pharmaceutical product development advancements and increased funding for neuropsychiatric products are evolving the market landscape. Although there are concerns with medication dependence, regulatory restrictions, and limited access to the discipline of sleep medicine in low socioeconomic regions, increased awareness of sleep health overall seems to outweigh these challenges.
 

Sleep Disorders Treatment Drugs Market Trends

The biggest trend likely within this treatment domain is the ever-pressing demand for safer, non-addictive therapies to replace sedative-oriented therapies such as melatonin receptor agonists, and orexin receptor antagonists, which provide useful therapy without the fear of addiction. As well, researchers and pharmaceuticals are assessing compounds looking to target the neurological factors causing sleep disorders, which should further enable precise, longer recovery.
 

Further, personalized medicine is gaining momentum, mainly in personalized therapy around genetics and behavior. The predicted increase in combination therapy that brings behavioral therapy with pharmacological treatment is a much larger lens of total treatment. Mark my words, this market is accelerating toward better, more patient-centered treatment models.
 

Furthermore, there is also a noteworthy shift to non-habit-forming medications available in the marketplace, such as the orexin receptor antagonists daridorexant and lemborexant, which have been approved respectively, are shown to be effective comparisons of treatment options for insomnia, but with lower dependency risk.
 

There is a growing use of Digital health technologies, including mobile applications and wearable devices, that help with diagnosis or for individualized therapy management plans, which demonstrates that there is a current re-evaluation of the process toward precision medicine as it comes to how sleep disorders are treated. These are a few examples of the movement toward the more holistic and patient-centered healthcare management of sleep disorders.
 

Sleep Disorders Treatment Drugs Market Analysis

The sleep disorders treatment drugs market from intrinsic sleep disorders-related segment had the highest market share in 2024 and is expected to continue to do so through 2034. With origins steeped in physiological or neurological issues manifesting in the body, intrinsic sleep disorders feature insomnia, narcolepsy, idiopathic hypersomnia, and restless legs syndrome, to name a few. Of these disorders, insomnia is by far the most common, affecting approximately > 30% of the adult population globally, at least once in their lives. The increased prevalence of chronic stress, mental health conditions such as anxiety and depression, and increasingly unregulated work-life schedules, has contributed to the number of persons diagnosed with intrinsic disorders is increasing.
 

In addition to these factors, unknown technological disruptions such as excessive screen time or too many night shifts destroying the circadian rhythm and disrupting the sleep-wake cycle, sleep disorders are becoming more commonplace. There is a myriad of pharmaceutical agents for treating intrinsic sleep disorders, whereby medications resulting in benzodiazepines, orexin antagonists, and melatonin-based pharmacotherapy designed to improve sleep quality, sleep-wake cycles, and daytime sleepiness.
 

The sleep disorders treatment drugs market from melatonin receptor agonists segment held a significant revenue share in 2024 and is projected to see steady growth through 2034. Melatonin receptor agonists are effective because they mimic the endogenous physiologic action of melatonin, a naturally occurring hormone regulating the sleep-wake cycle, particularly effective in sleep onset insomnia and circadian rhythm disorders. Unlike conventional sedatives, melatonin receptor agonists (such as ramelteon and tasimelteon) are non-scheduled, non-habit forming drugs that consist of minimal risk of dependent use, which improves their likability amongst health care providers as well as patients.
 

The absence of negative side effects and the assurance to maintain sleep architecture with minimal next-day impairment are additional characteristics of melatonin receptor agonists that have led to being widely used–especially in older populations sensitive to sedative-hypnotic drugs.
 

Additionally, a growing focus on safer, more naturalistic evidence-based therapies to treat chronic conditions has increased acceptance of melatonin receptor agonists in managed care, particularly when the therapy includes long-term management plans. The increase in jet lag, shift work disorder, and delayed sleep phase disorder—syndromes that closely relate to current modern work lifestyles—has also driven the demand for circadian rhythm-based therapies. Related to this topic, clinical studies are receiving funding for exploring the evidence-based therapeutic capability of melatonin receptor agonists in populations that include pediatric insomnia and neurodevelopment sleep disorders, providing other therapeutic avenues for considering a growing market segment.
 

Asia Pacific sleep disorders treatment drugs market is expected to achieve the fastest CAGR from 2025 to 2034. The region's mass-market potential and growing population (rapidly aging), rapid urbanization, increasing work-related stress, and the relatively recent adoption of Westernized lifestyles (particularly with technology use and exposure to artificial light), have contributed to the increases in sleep-related health issues. In Asia Pacific countries, such as China, Japan, India, and South Korea, traditional lifestyles involve sleeping well with natural light.
 

However, lifestyle transformations have shifted populations towards irregular sleep patterns and increased insomnia, sleep apnea, and circadian issues. Increased mental health awareness, sleeping hygiene, and access to healthcare services have contributed to increased attention to sleep disorders. In the last few years, the combination of awareness and access has driven overall demand for sleep disorder treatments, including pharmaceutical and alternative methods.
 

Furthermore, as healthcare in Asia has improved and access to quality healthcare services continues to improve, the whole subject of inheritance and genomic variations of this population is becoming more of a focus for novel treatments. Other potential pharmaceutical-based treatments in involved with discovery and development based on genetic and environmental factors, both of which are important to the Asia Pacific population.
 

Sleep Disorders Treatment Drugs Market Share

The sleep disorders treatment drugs industry players include:

• Athenex
• Ferring International Center
• Merck
• Heptares Therapeutics (Sosei Group Corporation)
• Evotec
• Galenica
• Astellas Pharma
• Eisai
• Alexza Pharmaceuticals (Ferrer Therapeutics, Inc.)
   

Key players in the sleep disorders treatment drugs market use various strategies to enhance their market position. This includes sustained investment in R&D to develop new, innovative therapies that are non-addictive and have favorable safety profiles and an improved side effect profile. Advancing the growth pipeline via strategic partnerships, licensing agreements, and mergers is also being used companies are focusing on growing their drug pipeline for the rapid reduction of business, through the development of emerging countries, including India and China. Product differentiation is also occurring in Sleep Disorders Treatments such as through novel drug delivery systems (sublingual tablets and extended-release formulation) that can help to enhance adherence by the patients.
 

Sleep Disorders Treatment Drugs Industry News

• In December 2024, Eli Lilly and Company stated that the U.S. Food and Drug Administration had approved Zepbound® (tripeptide) as the first and only prescription medication for adults diagnosed with moderate-to-severe obstructive sleep apnea (OSA) and obesity. They explained, “Zepbound was developed to help individuals with OSA and obesity manage their condition more effectively.” They added that the treatment was intended to be used alongside a reduced-calorie diet and increased physical activity to enhance its effectiveness. 
   
• In December 2024, Nxera Pharma and Shionogi & Co., Ltd., launched QUVIVIQ™ as a treatment for adult insomnia. The drug functioned as a Dual Orexin Receptor Antagonist (DORA), targeting the wake-promoting neuropeptides OX1R and OX2R to help initiate and maintain sleep. It minimized next-day drowsiness and was made available in 25 mg and 50 mg oral tablets.